ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers (GaGA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03411590
Recruitment Status : Not yet recruiting
First Posted : January 26, 2018
Last Update Posted : January 29, 2018
Sponsor:
Collaborator:
Lagos State University
Information provided by (Responsible Party):
FrieslandCampina WAMCO Nigeria PLC

Brief Summary:

It is well known than an important part of Nigerian children from the lower social economic class have nutrient deficiencies. Fortified products, such as growing up milks (GUM), may play an important role in reducing the risk and incidence of nutrient deficiencies. However, affordability of GUM is an issue.

In this project the effects are studied of different daily intakes of GUM on iron status, growth, several other nutrient status parameters in blood and urine, cognitive development, and the intestinal microbiome in Nigerian toddlers 1-3 years of age.

The project is a collaboration with the department of Paediatrics and Child health of the Lagos State University College of Medicine in Lagos. The design is based on a three-arm, open (partly blind: statistics, biochemical analyses), randomized intervention trial. Recruitment will take place in Ijora-Badia community in Apapa-Iganmu Local Council Development Area (LCDA) in Lagos. The three groups will be given a multi-micronutrient fortified growing-up milk (PEAK), in amounts of 200, 400 or 600 ml per day during a period of 6 months. Primary objective of this study is to reduce iron deficiency anemia. Based on this objective, in total 150 children have to be included in this study.


Condition or disease Intervention/treatment Phase
Malnutrition; Mild Iron-deficiency Anemia Nutritional Stunting Nutritional Wasting Nutritional Deficiency Enterobacteriaceae Infections Other: Fortified milk Powder Not Applicable

Detailed Description:

The present study will be a three-arm, open (partly blind) blind, randomized intervention trial in Nigerian children (12-36 months of age). Recruitment will take place in Ijora-Badia community in Apapa-Iganmu Local Council Development Area (LCDA), Lagos, South-West Nigeria. Ijora-Badia community has the highest burden of under-nutrition; In addition, it consists predominantly of low to middle socioeconomic status population, which is nationally representative, thus making it an ideal choice for this study. All families that are permanent residents of Ijora-Badia and have children aged 12-36 months will be invited to participate in the study. Before screening and recruitment will take place, parents or legal guardians of all potential candidates (toddlers) will be fully informed about the study, requirements and procedures. This means that at the day of screening, recruitment and enrolment, 10-20 children per day, fulfilling inclusion criteria, will be directly assigned to one of the three study groups when a written informed consent is obtained from the parents or legal guardians.

At the day of screening and recruitment, mothers will be required to bring their child to the clinic. At this initial screening toddlers will be evaluated to assess their eligibility for participation to the study according to the inclusion and exclusion criteria (i.e. anthropometric measurements, blood collection for the assessment of haemoglobin levels and information collected by parents). Those toddlers meeting all inclusion criteria will be considered as eligible and will be randomised to one of the three study groups. Prior to the initiation of the intervention, all eligible study participants will be dewormed (medicine, brand, dosage). Baseline measurements will take place that same day, and after 6 months of intervention: anthropometric measurement, a cognitive test (30 minutes), and venous blood sampling (8 ml). For food and nutrient intake indices, and faecal sampling, a proper planning will be made, to be sure that it takes place within 3 days following baseline measurements.

The three groups will be given a multi-micronutrient fortified growing-up milk, in amounts of 200, 400 or 600 ml per day. In case of 400 and 600 ml, the portions (200 ml each) will be spread during the day. Airtight packed portions of milk powder sachets will be delivered weekly at the families by field monitors who also provide instructions for use as well as collect empty sachets for a compliance check. Consumption of test product will start as soon as all baseline examinations and samples have been completed and collected, and will last for 6 months.

Prior to the initiation of the screening and recruitment phase, the study protocol will have to be approved by the Lagos State University Teaching Hospital Research/Ethics Committee, and has to be registered in an acknowledged trial register.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
Estimated Study Start Date : February 5, 2018
Estimated Primary Completion Date : September 8, 2018
Estimated Study Completion Date : January 24, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Arm Intervention/treatment
200ml
Toddlers will be allocated to the 200 ml group
Other: Fortified milk Powder
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)

400ml
Toddlers will be allocated to the 400 ml group
Other: Fortified milk Powder
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)

600ml
Toddlers will be allocated to the 600 ml
Other: Fortified milk Powder
Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)




Primary Outcome Measures :
  1. Iron deficiency anaemia [ Time Frame: 6 Months ]
    Prevalence of Iron deficiency anaemia as assessed by haemoglobin concentration


Secondary Outcome Measures :
  1. Hematocrit [ Time Frame: 6 months ]
    Hematocrit to substantiate the effect of iron supplementation on Hb

  2. Ferritin [ Time Frame: 6 months ]
    ferritin to substantiate the effect of iron supplementation on Hb concentration

  3. plasma concentrations of specific inflammation markers (i.e. C-Reactive) [ Time Frame: 6 months ]
    plasma concentrations of specific inflammation markers (i.e. C-Reactive)

  4. Weight [ Time Frame: 6 months ]
    Body weight for infants up to 24 months old

  5. Serum concentrations of specific micronutrient status [ Time Frame: 6 Months ]
    Serum concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.

  6. Parameters of cognitive development [ Time Frame: 6 Months ]
    Parameters of cognitive development such as Memory tests, attention tests,using screening version of the Bayley III Test for Children

  7. Recumbent length [ Time Frame: 6 months ]
    Length in meters and standing height for toddlers from 24 to 36 months old

  8. Plasma concentrations of specific micronutrient status [ Time Frame: 6 months ]
    Plasma concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.

  9. Urine concentrations of specific micronutrient status [ Time Frame: 6 Months ]
    Urine concentrations of specific micronutrient status indices, such as vitamins, minerals and trace elements.


Other Outcome Measures:
  1. intestinal microbiome [ Time Frame: 6 months ]
    intestinal microbiome in a subpopulation of infants to explore the effect of 2-7 mg of Fe per day (provided as ferrous-sulfate) on the numbers of and changes in Enterobacteriaceae



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 3 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Normal term birth (caesarean section excluded)
  2. Boys and girls in the age range of 12 to 36 months at enrolment
  3. Apparently healthy at screening (assessed with the use of a medical history record)
  4. Hb ≥70 g/L and ≤109 g/L, according to WHO guidelines 27
  5. Mild to moderate acute malnutrition (i.e. HAZ, WAZ <-1 SD and > -3 SD)
  6. Parents and/or legal guardians are residents of Oshodi LGA
  7. Parents and/or legal guardians do not plan to migrate during the study
  8. Written informed consent from parents and/or legal guardians
  9. Children able to consume a maximum of 96g (= 600 ml) of product per day

Exclusion Criteria:

  1. Severe anaemia (Hb<70 g/L) or normal Hb (Hb≥110 g/L)
  2. Severe acute malnutrition (HAZ, WAZ <-3 SD) requiring hospitalization
  3. Chronic or severe illness requiring hospitalisation and/or special treatment
  4. Recent medical history (past 3 months) of serious infections, injuries and/or surgeries
  5. Any known allergies or intolerances to milk or milk ingredients
  6. Predominantly breast-fed infants or toddlers
  7. Consumption of any other fortified foods or supplements
  8. Participation to other micronutrient supplementation programmes
  9. Participation to any other nutritional study in the last 6 months
  10. Participation to another clinical study or receipt of an investigational drug in the last 30 days
  11. Indication that they are likely to move within the period of study intervention
  12. Family members of employees of the Sponsor or the study site.
  13. Use of any prescription medications prior to and/or during the study period for more than or equal to two weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03411590


Contacts
Contact: Adedotun J Owolabi, MSc +23401271500 ext 2661 adedotun.owolabi@frieslandcampina.com
Contact: Anne Schaafsma, PhD +34582992424 anne.schafsma@frieslandcampina.com

Sponsors and Collaborators
FrieslandCampina WAMCO Nigeria PLC
Lagos State University
Investigators
Principal Investigator: Idowu O Senbanjo, MBBS LAGOS STATE UNIVERSITY COLLEGE OF MEDICINE

Responsible Party: FrieslandCampina WAMCO Nigeria PLC
ClinicalTrials.gov Identifier: NCT03411590     History of Changes
Other Study ID Numbers: 2017-GAGA-GND
First Posted: January 26, 2018    Key Record Dates
Last Update Posted: January 29, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Malnutrition
Anemia, Iron-Deficiency
Enterobacteriaceae Infections
Nutrition Disorders
Anemia, Hypochromic
Anemia
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Micronutrients
Trace Elements
Growth Substances
Physiological Effects of Drugs